# Bevacizumab Plus FSRT Versus Hippocampus-Avoidant WBRT in Lung Adenocarcinoma With Extensive Brain Metastases

Source: https://onco.cc/trials/nct07481786/  
OnCo record `nct07481786` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of bevacizumab in lung cancer, run by Sun Yat-sen University, now recruiting.

## Summary

Bevacizumab Plus FSRT Versus Hippocampus-Avoidant WBRT in Lung Adenocarcinoma With Extensive Brain Metastases is a phase 3, randomised interventional study registered as NCT07481786 by Sun Yat-sen University, with a registry enrolment figure of 220 participants, started 2026-03-20 and due to reach its primary completion in 2029-09-15. Interventions recorded: FSRT; HA-WBRT-SIB; Bevacizumab. Conditions listed: Lung Adenocarcinoma; Brain Metastases; Radiotherapy, Intensity-Modulated; Bevacizumab; Whole-Brain Radiotherapy. Primary outcome: Intracranial Progression-Free Survival (IPFS); Neurocognitive Function failure. Lung eligibility wording from the registry: "* Pathologically confirmed non-squamous non-small cell lung cancer (adenocarcinoma)". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT07481786
- Phase: 3
- Setting: Application of Bevacizumab Combined With Fractionated Stereotactic Radiotherapy (FSRT-Bev) Versus Hippocampus-Avoidant Whole-Brain Radiotherapy With Simultaneous Integrated Boost (HA-WBRT-SIB) in Patients With Extensive Brain Metastases From Lung Adenocarcinoma: A Phase III Randomized Controlled Trial Evaluating Intracranial Control Efficacy and Neurocognitive Function
- Sponsor: Sun Yat-sen University
- Enrolled: 220

## Sources

- ClinicalTrials.gov NCT07481786: https://clinicaltrials.gov/study/NCT07481786

## Connected records

- cancers: [Lung cancer (all types)](https://onco.cc/cancers/lung-cancer/)
- technologies: [Anti-angiogenic therapy](https://onco.cc/technologies/antiangiogenic/), [Monoclonal antibodies](https://onco.cc/technologies/monoclonal-antibody/), [SBRT / SABR (stereotactic radiotherapy)](https://onco.cc/technologies/sbrt/)
- drugs: [Bevacizumab](https://onco.cc/drugs/bevacizumab/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07481786.json